Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
by ecancer reporter Vanessa Lane
Allogeneic stem cell transplant (allo) in patients with multiple myeloma (MM) is a controversial treatment method.
A recent study of relapsed patients after autologous stem cell transplant (ASCT) showed that those patients treated with reduced intensity conditioning allo (RIC/allo) had better progression free survival (PFS) versus those patients who received novel therapies, but that overall survival (OS) was similar.
Upfront treatment with ASCT-RIC/allo has been more promising and has showed improvements in both PFS and OS versus ASCT alone in 2 out of 6 prospective trials. One of these studies was the EBMT-NMAM2000 study, which demonstrated significant improvements in PFS and OS for ASCT-RIC/allo versus ASCT alone at 96 months (22% vs 12% and 49% vs 36%, respectively).
Future clinical studies are needed to investigate the use of ASCT-RIC/allo in combination with novel therapies to establish whether it has a place in the upfront treatment of high risk patients and those experiencing relapse.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.